ENTITY
Kyowa Kirin Co Ltd

Kyowa Kirin Co Ltd (4151 JP)

48
Analysis
Health CareJapan
Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.
more
06 Apr 2018 13:44

Japan Pharma: Upcoming Catalysts & Event Driven Trading Ideas

Takeda Pharmaceutical Co Ltd (4502 JP), Shionogi & Co Ltd (4507 JP), Nippon Shinyaku Co Ltd (4516 JP) , Sumitomo Dainippon Pharma Co (4506 JP),...

09 Oct 2017 16:15

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...

21 Sep 2017 05:03

Large-Cap Names that Have Gotten a Lot More Volatile Recently....

We screened for large-cap names in Japan that have recently seen a spike in volatility. We calculated Beta over the last 6 months and compared it...

Logo
279 Views
Share
25 Apr 2017 06:06

Leakage Report - Names that Moved on Volume Yesterday, Days Before They Announce Earnings....

Through Earnings Season we like to track volume spikes pre-earnings announcement. For some of the volume spikes we can find legitimate reasons and...

Logo
258 Views
Share
10 Apr 2017 16:15

Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs

Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...

x